Difference between revisions of "Alisertib (MLN-8237)"
Jump to navigation
Jump to search
m |
m |
||
| Line 3: | Line 3: | ||
=Preliminary results= | =Preliminary results= | ||
| + | |||
| + | =[[Aggressive Non-Hodgkin lymphoma]]= | ||
| + | =[[Mantle cell lymphoma]]= | ||
| + | |||
# Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [http://jco.ascopubs.org/content/32/1/44.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24043741 PubMed] | # Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. [http://jco.ascopubs.org/content/32/1/44.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24043741 PubMed] | ||
Revision as of 03:50, 12 November 2014
Mechanism of action
Aurora A kinase (AAK) inhibitor
Preliminary results
Aggressive Non-Hodgkin lymphoma
Mantle cell lymphoma
- Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article PubMed